当前位置: X-MOL 学术Brain Behav. Immun. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Baseline high levels of complement component 4 predict worse clinical outcome at 1-year follow-up in first-episode psychosis
Brain, Behavior, and Immunity ( IF 15.1 ) Pub Date : 2020-08-01 , DOI: 10.1016/j.bbi.2020.01.014
Valeria Mondelli 1 , Marta Di Forti 2 , B Paul Morgan 3 , Robin M Murray 4 , Carmine M Pariante 1 , Paola Dazzan 5
Affiliation  

BACKGROUND Recent evidence has highlighted the potential role of complement component 4 (C4) in the development of schizophrenia. However, it remains unclear whether C4 is also relevant for clinical outcome and if it could be considered a possible therapeutic target. The aim of this naturalistic longitudinal study was to investigate whether baseline levels of C4 predict worse clinical outcome at 1-year follow-up in patients with first episode psychosis. METHODS Twenty-five patients with first episode psychosis were assessed at baseline and followed-up prospectively for their clinical outcome at 1 year from baseline assessment. Concentrations of complement component 4 (C4) were measured using ELISA methods from baseline serum samples. Twelve patients were classified as non-responders and 13 as responders. ANCOVA analyses were conducted to investigate differences in baseline C4 levels between responders and non-responders at 1-year covarying for baseline severity of symptoms and for levels of C reactive protein. RESULTS Non-responders show significantly higher baseline C4 levels compared with responders when controlling for baseline psychopathology and baseline levels of C reactive protein (552.5±31.3 vs 437.6±25.5 mcg/ml; p=0.008). When investigating the ability of C4 levels to distinguish responders from non-responders, we found that the area under the ROC curve was 0.795 and the threshold point for C4 to distinguish between responders and non-responders appear to be around 490 mcg/ml. CONCLUSIONS Our preliminary findings show that baseline C4 levels predict clinical outcome at 1-year follow-up in patients with first episode psychosis.

中文翻译:

基线高水平补体成分 4 预示首发精神病患者 1 年随访时临床结果较差

背景最近的证据强调了补体成分 4 (C4) 在精神分裂症发展中的潜在作用。然而,尚不清楚 C4 是否也与临床结果相关,以及它是否可以被视为可能的治疗靶点。这项自然纵向研究的目的是调查 C4 的基线水平是否能预测首发精神病患者在 1 年随访时的较差临床结果。方法 对 25 名首发精神病患者进行基线评估,并在基线评估后 1 年对他们的临床结果进行前瞻性随访。使用 ELISA 方法从基线血清样品中测量补体成分 4 (C4) 的浓度。12 名患者被归类为无反应者,13 名患者被归类为有反应者。进行 ANCOVA 分析以研究响应者和非响应者之间基线 C4 水平在 1 年共变时基线症状严重程度和 C 反应蛋白水平的差异。结果 在控制基线精神病理学和 C 反应蛋白基线水平时,与有反应者相比,无反应者显示出显着更高的基线 C4 水平(552.5±31.3 vs 437.6±25.5 mcg/ml;p=0.008)。在研究 C4 水平区分响应者和非响应者的能力时,我们发现 ROC 曲线下面积为 0.795,C4 区分响应者和非响应者的阈值似乎在 490 mcg/ml 左右。结论 我们的初步研究结果表明,基线 C4 水平可预测首发精神病患者 1 年随访时的临床结果。
更新日期:2020-08-01
down
wechat
bug